Want to see SE:ERMA full AI Analyst Report?
ERMA Stock Chart & Stats
kr1.91
-kr0.30(-12.50%)
At close: 4:00 PM EST
kr1.91
-kr0.30(-12.50%)
Day’s Range― - ―
52-Week Rangekr0.21 - kr3.00
Previous CloseN/A
Volume29.79K
Average Volume (3M)4.35K
Market Cap
kr22.38M
Enterprise Valuekr8.12M
Total Cash (Recent Filing)kr17.76M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding74,588,684
10 Day Avg. Volume2,975
30 Day Avg. Volume4,348
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.66
Price to Sales (P/S)48.45
P/FCF Ratio-2.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageNear-zero debt materially reduces insolvency risk and interest burden, giving management structural flexibility to pursue licensing or partnership-led commercialization. This durable capital structure lowers fixed obligations and extends runway versus highly leveraged peers.
Demonstrated Positive Gross Profit YearRecording positive gross profit in 2024 indicates the product economics can cover direct costs at some scale or under certain conditions. That suggests underlying unit economics may be viable long-term if commercial scale or partner manufacturing improves consistency.
Partnership/Licensing-Focused Business ModelA focus on licensing and partner commercialization aligns with a low-capex, scalable model that can convert R&D into recurring royalties and milestone income. Structurally this reduces manufacturing and distribution risk and supports faster scalability if partners are secured.
Bears Say
Very Small And Declining RevenueA tiny, shrinking revenue base undermines ability to fund operations internally and signals weak commercial traction. Over a multi-month horizon, persistently falling sales erode bargaining power with partners and make sustaining R&D and regulatory activities harder without external financing.
Negative Shareholders' EquityNegative equity is a structural red flag that constrains financial flexibility and may limit access to non-dilutive financing. It implies accumulated losses and likely dependence on capital raises, which can dilute shareholders and complicate long-term planning for commercialization.
Persistent Cash BurnLarge, ongoing negative operating and free cash flow indicate the company must secure external funding to continue operations. This persistent cash burn creates execution risk, potential dilution from financing, and pressure to sign partnerships or asset sales under suboptimal terms.
ERMA FAQ
What was Enorama Pharma AB’s price range in the past 12 months?
Enorama Pharma AB lowest stock price was kr0.21 and its highest was kr3.00 in the past 12 months.
What is Enorama Pharma AB’s market cap?
Enorama Pharma AB’s market cap is kr22.38M.
When is Enorama Pharma AB’s upcoming earnings report date?
Enorama Pharma AB’s upcoming earnings report date is Aug 19, 2026 which is in 14 days.
How were Enorama Pharma AB’s earnings last quarter?
Enorama Pharma AB released its earnings results on May 20, 2026. The company reported -kr0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.17.
Is Enorama Pharma AB overvalued?
According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued.
Does Enorama Pharma AB pay dividends?
Enorama Pharma AB does not currently pay dividends.
What is Enorama Pharma AB’s EPS estimate?
Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enorama Pharma AB have?
Enorama Pharma AB has 74,588,684 shares outstanding.
What happened to Enorama Pharma AB’s price movement after its last earnings report?
Enorama Pharma AB reported an EPS of -kr0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 23.333%.
Which hedge fund is a major shareholder of Enorama Pharma AB?
Currently, no hedge funds are holding shares in SE:ERMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.